|Bid||2.1700 x 800|
|Ask||2.1800 x 4000|
|Day's Range||2.1550 - 2.2206|
|52 Week Range||2.0000 - 5.9900|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||217.50|
|Earnings Date||Nov 01, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AMRX
BRIDGEWATER, N.J., October 03, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
In this article, we discuss the 10 best 52-week low small-cap stocks to buy now. If you want to skip our discussion on the overall economic environment in the US, go to 5 Best 52-Week Low Small-Cap Stocks to Buy Now. The US stock markets have come under pressure as inflation rose faster than expected […]
BRIDGEWATER, N.J., September 06, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.